The short answer
PLATEAU (NCT07446998) is a Phase 2b trial of enobosarm added to semaglutide in 239 adults aged 65 and over. Its predecessor QUALITY had total lean body mass as its primary endpoint; PLATEAU's registered primary endpoint is instead total body weight, measured at day 476.
Key facts
- PLATEAU registration
- NCT07446998
- Registered acronym
- PLATEAU
- Design
- Phase 2b, randomised, triple-masked, placebo-controlled
- Enrolment
- 239 (actual); active, not recruiting
- Population
- Aged 65 and over
- Primary endpoint
- Total body weight versus semaglutide alone, at day 476
- Predecessor
- QUALITY (NCT06282458), 168 actual, completed 11 April 2025
- QUALITY primary endpoint
- Percentage change in total lean body mass at 112 days
- Registry checked
- ClinicalTrials.gov, 21 November 2026
What is being tested
Enobosarm is a selective androgen receptor modulator, given orally. The rationale for combining it with a GLP-1 receptor agonist is the lean-mass question: substantial weight loss on incretin therapy includes a proportion of fat-free mass, and an agent that preserves muscle during that loss would change the composition of what is lost. Veru's programme has run two trials on this combination. QUALITY (NCT06282458) was a Phase 2 dose-finding study of 168 participants aged 60 and over, comparing semaglutide plus enobosarm 3 mg or 6 mg daily against a GLP-1 receptor agonist plus placebo, and it completed on 11 April 2025. PLATEAU (NCT07446998) is the Phase 2b successor: 239 participants aged 65 and over, semaglutide plus enobosarm 3 mg against semaglutide plus placebo, started 26 March 2026 with primary completion in October 2027.
The endpoint changed, and that is the story
QUALITY's primary endpoint, as registered, was the percentage change from baseline in total lean body mass at 112 days. That is the mechanistic endpoint: it measures the thing the drug is supposed to do. PLATEAU's registered primary endpoint is to determine the effect of enobosarm in combination with semaglutide on total body weight compared with semaglutide alone, at day 476. Total fat mass appears as a secondary endpoint. That is a different question about the same combination, over four times the duration.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Why the direction of that endpoint is not obvious
For an agent whose purpose is preserving lean mass, an effect on total body weight is ambiguous. Muscle is denser than fat and contributes mass; successfully preserving lean tissue while fat is lost could leave total weight loss unchanged or smaller than semaglutide alone produces. A trial whose primary endpoint is total body weight is therefore not straightforwardly testing the mechanistic hypothesis, and the endpoint that would test it most directly (fat mass, or the ratio of fat to lean loss) sits in the secondary position. This is not a criticism of the design, which may reflect what a regulator has indicated it wants to see; it is a reason to read the eventual result carefully rather than as a simple test of muscle preservation.
The populations are narrow, and deliberately so
QUALITY enrolled adults aged 60 and over; PLATEAU raises that to 65 and over. Older adults lose proportionally more lean mass during weight reduction and have less to spare, so the concern the drug addresses is concentrated in that group. It also means neither trial says anything about younger populations, and results from either should not be generalised beyond the age range enrolled. Both trials are triple-masked, which is a stronger masking specification than the double-blind description usually reported.
Where this sits among muscle-preservation programmes
Several approaches are being tried against the same problem by different mechanisms: activin receptor pathway blockade, myostatin-directed agents, and selective androgen receptor modulation as here. None has produced a licensed agent for this purpose, and the field has already produced one instructive failure in bimagrumab's withdrawn trial. The common difficulty is that preserving lean mass is easy to demonstrate on a scan and hard to connect to an outcome anyone can feel, which is why physical function measures appear in these designs alongside body composition.
What this does not mean
Enobosarm is investigational and is not licensed anywhere for weight management or muscle preservation. Selective androgen receptor modulators are not supplied on this site and nothing here is a version of one. Semaglutide is a licensed prescription medicine; research material is not an alternative to it, and the dose arms described here are facts about registered trials conducted under clinical supervision, not guidance of any kind.
Quick reference
| QUALITY | PLATEAU | |
|---|---|---|
| Registration | NCT06282458 | NCT07446998 |
| Phase | 2 | 2b |
| Enrolment | 168 (actual) | 239 (actual) |
| Age | 60 and over | 65 and over |
| Primary endpoint | Total lean body mass | Total body weight |
| Timepoint | 112 days | Day 476 |
| Status | Completed 11 April 2025 | Active, not recruiting |
Frequently asked questions
Has PLATEAU finished enrolling?
Yes. On 21 November 2026 the registry listed it as active, not recruiting, with an actual enrolment of 239 (it had shown 200 as an estimate). Company announcements about enrolment milestones routinely precede the registry record being updated, so the two can disagree for a period; the registry is the record that can be checked.
What did QUALITY find?
Its registered primary endpoint was percentage change in total lean body mass at 112 days and it completed in April 2025. Any figure quoted for it should be traced to a published report or a company release rather than inferred from the trial's existence.
Is a SARM the same kind of thing as a GLP-1 drug?
No. Enobosarm acts at the androgen receptor; incretin agents act at gut hormone receptors. They are combined here because they address different components of the same outcome, not because they share a mechanism.
Why does the age threshold matter?
Because lean mass loss during weight reduction is a larger concern in older adults, who have less reserve. It also limits what the trials can support: neither enrolled younger participants, so neither speaks to them.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Research & Regulatory News articles
- Four Arms, and Where the Participants WentREDEFINE 1 randomised 3,417 adults to CagriSema, semaglutide alone, cagrilintide alone or placebo. Its allocation ratio says what it was designed to answer.
- Less Weight Loss, and That Is the Expected ResultREDEFINE 2 reported a -13.7% weight change in adults with type 2 diabetes, against -20.4% in the trial without diabetes. That gap is a well-documented pattern.
- Superior to Semaglutide, by 0.16 Percentage PointsREIMAGINE 2 made semaglutide its primary comparator rather than placebo. The combination won, and the size of that win is the part actually worth reading.
- 7,101 Participants, and No Answer Until 2027REDEFINE 3 is the CagriSema cardiovascular outcomes trial. It enrolled 7,101 participants, and its primary completion date is not until September 2027.
- Orforglipron (Foundayo): The MHRA Approval, ExplainedThe MHRA authorised orforglipron (Foundayo) on 10 August 2026 - Europe's first oral GLP-1 pill. Approved indications, trial data and the NICE timeline.